<DOC>
	<DOC>NCT00763568</DOC>
	<brief_summary>The purpose of this study is to determine if taking nitazoxanide alone for 4 weeks followed by 36 weeks of nitazoxanide plus peginterferon is superior to peginterferon plus ribavirin (standard of care) for 48 weeks.</brief_summary>
	<brief_title>4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>Chronic hepatitis C Previously failed to respond to at least 12 weeks of peginterferon plus ribavirin combination therapy. Unable to take oral medication. Females who are either pregnant, breastfeeding or not using birth control. Males whose female partners are pregnant or plan to become pregnant. Other causes of liver disease (for example, autoimmune hepatitis, decompensated liver disease). Patients with HIV, HAV, HBV or HDV. Patients with a history of alcoholism or with an alcohol consumption of more than 40 grams per day. Patients with hemoglobinopathies (for example, thalassemia major, sicklecell anemia). History of hypersensitivity or intolerance to nitazoxanide or peginterferon.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Viral hepatitis</keyword>
</DOC>